Matthew Kulke, MD
Zoltan Kohn Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MD, University of California, San Francisco
MMS/MMSc, Harvard Medical School
BA, Princeton University

Matthew Kulke MD is the Chief of Hematology/Oncology, Co-Director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Chobanian and Avedisian School of Medicine. Dr. Kulke is an internationally recognized for his work in the field of neuroendocrine tumors. He has led or co-led both early and late stage clinical trials leading to the development of telotristat ethyl, temozolomide, sunitinib, everolimus and peptide receptor radiotherapy for the treatment of neuroendocrine tumors. His work has additionally included characterization of neuroendocrine tumors at the molecular level, and has resulted in over 200 peer-reviewed publications.

Dr. Kulke received his undergraduate degree in molecular biology from Princeton University magna cum laude, and his medical degree with a thesis honors award from the University of California, San Francisco School of Medicine where he also was a Regent’s scholar and received a research training fellowship from the Howard Hughes Medical Institute. He performed his internship and residency at Brigham and Women’s Hospital, a medical oncology fellowship at Dana-Farber Cancer Institute, and received a Masters in Medical Science Degree from Harvard Medical School.

Prior to coming to Boston University he was a Professor of Medicine at Harvard Medical School and Director of the Neuroendocrine Tumor Program at Dana-Farber Cancer Institute. He has served as principal investigator for NCI cooperative group trials in both neuroendocrine tumors and pancreatic cancer, served as chair of the National Cancer Institute’s Neuroendocrine Tumor Clinical Trial Task Force, chair of the North American Neuroendocrine Tumor Society, and chair of the National Comprehensive Cancer Network’s neuroendocrine tumor guidelines committee.

Diversity, Equity, Inclusion and Accessibility

Our commitment as a section to DEIA is reflected broadly- in the way in which we care for our diverse patient population, the way in which we perform research, and the way in which we interact with each other as faculty and staff. Our institutional commitment, "exceptional care without exception" reflects these values, and we are equally committed to ensuring that our research efforts appropriately reflect and impact the diverse and multicultural society in which we live. To build on these efforts, we are supporting a designated leadership position to lead DEI efforts within the section, have monthly meetings of an anti-racism committee, sponsor workshops and speakers, and commit part of every section meeting to reviewing topics related to Diversity, Equity, Inclusion and Accessibility. Recognizing that advancing DEIA is a journey, our goal is to be leaders on this path. We are firm in the knowledge that our continued and future success is predicated on an open and inclusive environment, and on the unparalleled strength provided by the diverse backgrounds, talents and perspectives of our patients, staff, and faculty.

Section Chief
Boston Medical Center
Hematology & Medical Oncology

Boston University
BU-BMC Cancer Center

Boston University
Evans Center for Interdisciplinary Biomedical Research

Multidimensional IO markers of Response and Resistance to Checkpoint Inhibition
09/13/2018 - 09/12/2026 (PI)
Bristol-Myers Squibb Company

A novel, dual targeted theranostic approach to the treatment of pancreatic cancer
07/01/2023 - 06/30/2026 (PI)
Boston Children's Hospital

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
03/01/2023 - 02/28/2026 (PI)
Dana Farber Cancer Institute National Cancer Inst

Cancer-Associated Thromboembolism as Affected by Health Disparities (CAT-HD)
07/01/2021 - 06/30/2025 (PI)
Trustees of Boston University,CRC American Heart Assoc

ACS Patient Transportation Grant Application
04/01/2023 - 03/31/2025 (PI)
American Cancer Society

SWOG Clinical Trials
03/01/2019 - 02/28/2025 (PI)
Oregon Health and Science University National Cancer Inst

SWOG - Clinical Trials Initiative
03/01/2018 - 02/28/2025 (PI)
South West Oncology Group National Cancer Inst

Pre notification Sara Elizabeth O'Brien Trust Application
10/10/2023 - 10/09/2024 (PI)
Sara Elizabeth O'Brien Trust

Patient Navigation
08/01/2020 - 07/31/2024 (PI)
Jack Satter Foundation, Inc.

Phase II trial of cabozantinib in combination with nivolumab for advanced carcinoid tumors
05/22/2021 - 05/21/2024 (PI)
Dana Farber Cancer Institute

Showing 10 of 20 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Hernando J, Roca-Herrera M, García-Álvarez A, Raymond E, Ruszniewski P, Kulke MH, Grande E, Carbonero RG, Castellano D, Salazar R, Ibrahim T, Teule A, Alonso V, Fazio N, Valle JW, Tafuto S, Carmona A, Navarro V, Capdevila J. Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48]. Eur J Cancer. 2024 May; 203:114061. PMID: 38609739
  2. Burns L, Tukachinsky H, Raskina K, Huang RSP, Schrock AB, Sands J, Kulke MH, Oxnard GR, Tapan U. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma. Lung Cancer. 2024 Feb; 188:107454.View Related Profiles. PMID: 38159439
  3. Hoffman SE, Dowrey TW, Villacorta Martin C, Bi K, Titchen B, Johri S, DelloStritto L, Patel M, Mackichan C, Inga S, Chen J, Grimaldi G, Napolitano S, Wakiro I, Wu J, Yeung J, Rotem A, Sicinska E, Shannon E, Clancy T, Wang J, Denning S, Brais L, Besson NR, Pfaff KL, Huang Y, Kao KZ, Rodig S, Hornick JL, Vigneau S, Park J, Kulke MH, Chan J, Van Allen EM, Murphy GJ. Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors. Sci Adv. 2023 Sep 29; 9(39):eadd9668.View Related Profiles. PMID: 37756410; PMCID: PMC10530100; DOI: 10.1126/sciadv.add9668;
  4. Hernando J, Roca-Herrera M, García-Álvarez A, Raymond E, Ruszniewski P, Kulke MH, Grande E, García-Carbonero R, Castellano D, Salazar R, Ibrahim T, Teule A, Alonso V, Fazio N, Valle JW, Tafuto S, Carmona A, Navarro V, Capdevila J. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2023 Jul; 188:39-48. PMID: 37196483
  5. Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 Mar 01; 41(7):1359-1369. PMID: 36260828; PMCID: PMC9995105; DOI: 10.1200/JCO.22.01013;
  6. Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen JN, Enzinger AC, Clark JW, Chan JA. A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors. Pancreas. 2022 Aug 01; 51(7):763-768. PMID: 36395401
  7. Perez K, Jacene H, Hornick JL, Ma C, Vaz N, Brais LK, Alexander H, Baddoo W, Astone K, Esplin ED, Garcia J, Halperin DM, Kulke MH, Chan JA. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 Sep 01; 29(9):533-544. PMID: 35731023
  8. Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr Relat Cancer. 2022 May 09; 29(6):335-344. PMID: 35324465; PMCID: PMC9257687; DOI: 10.1530/ERC-21-0239;
  9. Perez K, Kulke MH, Chittenden A, Ukaegbu C, Astone K, Alexander H, Brais L, Zhang J, Garcia J, Esplin ED, Yang S, Da Silva A, Nowak JA, Yurgelun MB, Garber J, Syngal S, Chan J. Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs). JCO Precis Oncol. 2021 11; 5:808-816. PMID: 34994613
  10. Nadjarian A, LeClair J, Mahoney TF, Awtry EH, Bhatia JS, Caruso LB, Clay A, Greer D, Hingorani KS, Horta LFB, Ibrahim M, Ieong MH, James T, Kulke MH, Lim R, Lowe RC, Moses JM, Murphy J, Nozari A, Patel AD, Silver B, Theodore AC, Wang RS, Weinstein E, Wilson SA, Cervantes-Arslanian AM. Validation of a Crisis Standards of Care Model for Prioritization of Limited Resources During the Coronavirus Disease 2019 Crisis in an Urban, Safety-Net, Academic Medical Center. Crit Care Med. 2021 10 01; 49(10):1739-1748.View Related Profiles. PMID: 34115635; PMCID: PMC8439631; DOI: 10.1097/CCM.0000000000005155;
Showing 10 of 229 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 229 publications over 27 distinct years, with a maximum of 24 publications in 2017


2017 Neuroendocrine Tumor Research Foundation: Lauren Erb Award for Contributions to Neuroendocrine Tumor Research
2011 Dana-Farber Cancer Institute: Kenneth E Schwarz Center Compassionate Care Giver Award
2010 Dana-Farber Cancer Institute: Lee Nadler Extra Mile Award
2009 University of Pittsburgh School of Medicine: Ruth Brufsky Award for Excellence in Clinical Research on Pancreatic Cancer Research
2008 Dana-Farber Cancer Institute: Kenneth E Schwarz Center Compassionate Care Giver Award
2003 Dana-Farber Cancer Institute: George Canellos Award for Contributions to Clinical Research
1999-2001 Dana-Farber Cancer Institute: Discovery Fellowship
1998-1999 American Society of Clinical Oncology: Young Investigator Award
1992 UC San Francisco School of Medicine: Thesis Honors Award
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Gastrointestinal Oncology
Neuroendocrine Tumors
Novel Therapeutics
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map

Kulke's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department